Leukemia research最新文献

{"title":"NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia","authors":"Huan Wu ,&nbsp;Hang Luo ,&nbsp;Meng Wang ,&nbsp;YuQing Du ,&nbsp;Jiajia Li","doi":"10.1016/j.leukres.2024.107623","DOIUrl":"10.1016/j.leukres.2024.107623","url":null,"abstract":"<div><div>Acute myeloid leukaemia (AML) is a haematological malignancy that poses a serious threat to human health. Studies have shown that the expression of NAP1L5 is elevated in patients with AML; however, the specific molecular mechanism remains unknown. Therefore, in this study, we aimed to investigate the pathogenic mechanisms of NAP1L5 in AML. The expression level of NAP1L5 was increased in AML, and the upregulation of NAP1L5 was related to tumour growth and epithelial–mesenchymal transition. Furthermore, PEG10 is a downstream regulatory factor of NAP1L5, and its overexpression promotes tumour growth and epithelial–mesenchymal transition. More importantly, the loss of PEG10 inhibited the negative effects induced by NAP1L5 overexpression. Our results suggest that NAP1L5 is a novel therapeutic target for AML treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107623"},"PeriodicalIF":2.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide","authors":"Demei Feng,&nbsp;Shenrui Bai,&nbsp;Dong Liang,&nbsp;Xiaoqin Chen,&nbsp;Zhongjun Xia,&nbsp;Yang Liang,&nbsp;Hua Wang","doi":"10.1016/j.leukres.2024.107622","DOIUrl":"10.1016/j.leukres.2024.107622","url":null,"abstract":"<div><h3>Background</h3><div>Double-expressor diffuse large B-cell lymphoma (DE-DLBCL) has a poor prognosis, and optimal treatment strategies remain unclear. This study evaluates the efficacy and safety of RCHOP, R2-CHOP (RCHOP plus lenalidomide), and RCHOP plus Bruton's Tyrosine Kinase inhibitors (BTKi) in DE-DLBCL treatment.</div></div><div><h3>Methods</h3><div>Data from 213 DE-DLBCL patients treated from January 2019 and February 2024. Among them, 112 received R-CHOP, 65 received R2-CHOP, and 36 received R-CHOP plus BTKi. We evaluated clinical characteristics, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) for each groups.</div></div><div><h3>Results</h3><div>Baseline characteristics were comparable across groups. ORRs were 95.5 % for R-CHOP, 96.9 % for R2-CHOP, and 97.2 % for R-CHOP plus BTKi, with CR rates of 76.5 %, 80 %, and 75 %, respectively. BTKi significantly improved PFS (p=0.033) but not affect OS (p=0.165). Lenalidomide showed no benefit in PFS (p=0.153) or OS (p=0.351). With median follow-up times of 20.6 months for R-CHOP, 23.5 months for R2-CHOP, and 17.6 months for R-CHOP plus BTKi, the 1-year PFS rates were 73.6 %, 82.2 %, and 93.3 %, and the 1-year OS rates were 96.2 %, 93.2 %, and 100 %, respectively. Grade 3–4 adverse events included leukopenia, neutropenia, and anemia, and thrombocytopenia, with no significant differences among groups.</div></div><div><h3>Conclusion</h3><div>The addition of BTK inhibitor enhances progression-free survival in DE-DLBCL, especially in advanced-stage patients, without introducing new severe adverse reactions. In contract, adding lenalidomide does not offer additional efficacy or survival benefits.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107622"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study","authors":"Suying Qian,&nbsp;Jiali Gong,&nbsp;Xiu Shen,&nbsp;Mengjie Chen,&nbsp;Yiquan Cheng,&nbsp;Jingwen Zhu,&nbsp;Mengmeng Huang,&nbsp;Zhilong Shi,&nbsp;Gangfeng Xiao,&nbsp;Keyue Hu,&nbsp;Kesang Li","doi":"10.1016/j.leukres.2024.107621","DOIUrl":"10.1016/j.leukres.2024.107621","url":null,"abstract":"<div><h3>Introduction</h3><div>The direct causal relationship between these anomalies and chronic lymphatic leukemia (CLL) remains ambiguous. This study sought to investigate the potential causal link between immune cells and CLL.</div></div><div><h3>Materials and methods</h3><div>The summary data for genome-wide association studies utilized in this research were sourced from various publicly accessible databases, including the GWAS and FinnGen databases. By amalgamating these extensive genetic resources, we applied an array of cutting-edge Mendelian randomization (MR) analytical techniques. Specifically, we employed the inverse variance weighting (IVW) method, the weighted median method, the MR-Egger method, the Cochran Q test, Leave-One-Out sensitivity analysis, and the weighted model method to rigorously evaluate the potential causal link between multiple immune cell phenotypes and CLL.</div></div><div><h3>Results</h3><div>IVW analyses consistently demonstrated significant causal associations between five groups of immune cells and CLL. These associations were observed in both forward MR analyses from immune cells to CLL, and reverse MR analyses from CLL to immune cells. The five groups of immune cells under investigation included CD14+ CD16- monocyte Absolute Count, CD4+CD8+ T cell Absolute Count, BAFF-R on IgD- CD27- B cell, HLA DR+ T cell Absolute Count, and CD4+ T cell Absolute Count. Further sensitivity analyses not only confirmed the consistency in the direction of the association but also ruled out potential heterogeneity and horizontal pleiotropy effects. This enhanced the robustness and reliability of the study findings.</div></div><div><h3>Conclusion</h3><div>This investigation discerned definitive causal links between five immune cell phenotypes and CLL, underscoring the pivotal role of immune cells in the pathogenesis of this disease.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107621"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience","authors":"Giovanna Lucchini,&nbsp;Elena Cozma,&nbsp;Aimee Jackson,&nbsp;Kimberly Gilmour,&nbsp;Rachel Protheroe,&nbsp;Keith Wilson,&nbsp;Karl Peggs,&nbsp;Victoria Potter,&nbsp;Anne Parker,&nbsp;Andy Peniket,&nbsp;Eleni Tholouli,&nbsp;Robert Wynn,&nbsp;Emma Nicholson,&nbsp;Charles Craddock,&nbsp;David I. Marks,&nbsp;Christopher Parrish,&nbsp;Shankara Paneesha,&nbsp;Oana Mirci-Danicar,&nbsp;Alexander M. Martin,&nbsp;Graham McIlroy,&nbsp;Persis J. Amrolia","doi":"10.1016/j.leukres.2024.107618","DOIUrl":"10.1016/j.leukres.2024.107618","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107618"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report","authors":"Xiaomei Wang,&nbsp;Tao Chen","doi":"10.1016/j.leukres.2024.107616","DOIUrl":"10.1016/j.leukres.2024.107616","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107616"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center","authors":"Xianbo Huang ,&nbsp;Xianhui Wu ,&nbsp;Shasha Wang ,&nbsp;Yanling Ren ,&nbsp;Yu Xu ,&nbsp;Chen Mei ,&nbsp;Jie Jin ,&nbsp;Hongyan Tong ,&nbsp;Jiejing Qian","doi":"10.1016/j.leukres.2024.107617","DOIUrl":"10.1016/j.leukres.2024.107617","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107617"},"PeriodicalIF":2.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes of death in patients with myelodysplastic syndrome and spliceosome mutations","authors":"Panayiotis D. Kontoyiannis ,&nbsp;Arjun S. Peddireddy ,&nbsp;Koji Sasaki,&nbsp;Kelly Chien,&nbsp;Jayastu Senapati,&nbsp;Guillermo Montalban-Bravo,&nbsp;Courtney DiNardo,&nbsp;Gautam Borthakur,&nbsp;Rashmi Kanagal-Shamanna,&nbsp;Carlos Bueso-Ramos,&nbsp;Sherry Pierce,&nbsp;Hagop Kantarjian,&nbsp;Guillermo Garcia-Manero,&nbsp;Samuel Urrutia","doi":"10.1016/j.leukres.2024.107612","DOIUrl":"10.1016/j.leukres.2024.107612","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107612"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","authors":"Jiwei Shen ,&nbsp;Jiawei Li ,&nbsp;Rui Yang ,&nbsp;Shuang Wu ,&nbsp;Zhimei Mu ,&nbsp;Shi Ding ,&nbsp;Xinyu Zhang ,&nbsp;Meiying Duo ,&nbsp;Ye Chen ,&nbsp;Ju Liu","doi":"10.1016/j.leukres.2024.107615","DOIUrl":"10.1016/j.leukres.2024.107615","url":null,"abstract":"<div><div>Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107615"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population","authors":"V. Wais,&nbsp;A. Gantner,&nbsp;K. Strauss,&nbsp;A. Neagoie,&nbsp;C. Weidt,&nbsp;J. Schnell,&nbsp;H. Döhner,&nbsp;D. Bunjes,&nbsp;E. Sala","doi":"10.1016/j.leukres.2024.107611","DOIUrl":"10.1016/j.leukres.2024.107611","url":null,"abstract":"<div><div>Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107611"},"PeriodicalIF":2.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar,&nbsp;Arunan Jeyakumar,&nbsp;Alfred K. Lam,&nbsp;Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}